menu
    • menu
    [{"orgOrder":0,"company":"Attralus","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Attralus","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Attralus"},{"orgOrder":0,"company":"Attralus","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Attralus","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Attralus"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"124-I AT03","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"99m-Tc p5+14","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Attralus","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Attralus"},{"orgOrder":0,"company":"Attralus","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AT02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Attralus \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Novotech"},{"orgOrder":0,"company":"Attralus","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Novotech"},{"orgOrder":0,"company":"Attralus","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Venbio Partners","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Venbio Partners"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Ossianix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody-peptide Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Attralus \/ Attralus","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ Attralus"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"University of Tennessee Graduate School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ University of Tennessee Graduate School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ University of Tennessee Graduate School of Medicine"},{"orgOrder":0,"company":"Attralus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"I124-AT01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Attralus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Undisclosed"},{"orgOrder":0,"company":"Attralus","sponsor":"Sharmila Dorbala","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Sharmila Dorbala","highestDevelopmentStatusID":"10","companyTruncated":"Attralus \/ Sharmila Dorbala"}]

    Find Clinical Drug Pipeline Developments & Deals by Attralus

    Menu

    Attralus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 124-I Evuzamitide

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Recipient : University of Tennessee Graduate School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

                            Details : 124-I Evuzamitide is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lumbar Spinal Stenosis.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : 124-I Evuzamitide

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Recipient : University of Tennessee Graduate School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 124-I Evuzamitide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Sharmila Dorbala

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

                            Details : 124-I Evuzamitide is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : 124-I Evuzamitide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Sharmila Dorbala

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-02

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Attralus AT-02 Receives FDA Orphan Drug Designation for ATTR

                            Details : AT-02, a humanized IgG1 monoclonal antibody, company’s lead pan-amyloid removal therapeutic candidate for transthyretin-associated amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 12, 2024

                            Lead Product(s) : AT-02

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-02

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Attralus Receives EMA COMP Positive Opinions for AT-02 in ATTR and AL Amyloidosis

                            Details : AT-02, a humanized IgG1 monoclonal antibody, company’s lead pan-amyloid removal therapeutic candidate for transthyretin-associated amyloidosis and immunoglobulin light-chain-associated amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : AT-02

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-02

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Alpha Wave Ventures

                            Deal Size : $56.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Attralus Closes $56 Million Financing

                            Details : Attralus will use funds to advance Phase 1/2 development of AT-02, a humanized monoclonal antibody for treating transthyretin-associated amyloidosis and AL amyloidosis patients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            February 06, 2024

                            Lead Product(s) : AT-02

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Alpha Wave Ventures

                            Deal Size : $56.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc p5+14

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : University of Tennessee Graduate School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

                            Details : 99m-Tc p5+14 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 19, 2023

                            Lead Product(s) : 99m-Tc p5+14

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : University of Tennessee Graduate School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT02

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of AT-02 in Subjects With Systemic Amyloidosis.

                            Details : AT02 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 18, 2023

                            Lead Product(s) : AT02

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Novotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-04

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodeg...

                            Details : AT-04 is a fusion of our pan amyloid removal (PAR) peptide technology with the Fc component of a human IgG1 antibody. The PAR-peptide can bind to pathological protein fibrils found in neurogenerative diseases. The Fc stimulates the immune system to remov...

                            Product Name : Undisclosed

                            Product Type : Antibody-peptide Conjugate

                            Upfront Cash : Inapplicable

                            April 03, 2023

                            Lead Product(s) : AT-04

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 124-I Evuzamitide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

                            Details : 124-I Evuzamitide is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 02, 2022

                            Lead Product(s) : 124-I Evuzamitide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Columbia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Attralus

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-04

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Ossianix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Deliv...

                            Details : Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.

                            Product Name : Undisclosed

                            Product Type : Antibody-peptide Conjugate

                            Upfront Cash : Undisclosed

                            November 17, 2022

                            Lead Product(s) : AT-04

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Ossianix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth